Interventional Study of Wellbutrin XL in Major Depressive Disorder With Atypical Features
Status:
Completed
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
The aims of this study are 1) to examine the clinical utility of bupropion hydrochloride
extended release (Wellbutrin XL®) in patients with Major Depressive Disorder (MDD) with
atypical features; 2) to evaluate the tolerability of bupropion hydrochloride extended
release (Wellbutrin XL®) in patients with MDD with atypical features.